Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11783366 Combination therapies

Patent 11783366 was granted and assigned to Genentech on October, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
Genentech
Genentech
Date Filed
August 9, 2021
Date of Patent
October 10, 2023
Patent Applicant
Genentech
Genentech
Patent Application Number
17444691
Patent Citations
‌
US Patent 7511058 Heterocyclic inhibitors of MEK and methods of use thereof
‌
US Patent 7144907 Heterocyclic inhibitors of MEK and methods of use thereof
‌
US Patent 7307071 RAF-MEK-ERK pathway inhibitors to treat cancer
‌
US Patent 7378423 Pyrimidine compound and medical use thereof
‌
US Patent 7491829 RAF inhibitor compounds and methods
‌
US Patent 7504509 Compounds and methods for development of Ret modulators
‌
US Patent 8268852 Heterocyclic inhibitors of MEK and methods of use thereof
‌
US Patent 8394795 Pyrazole [3, 4-B] pyridine Raf inhibitors
‌
US Patent 8415345 Benzene sulfonamide thiazole and oxazole compounds
‌
US Patent 8426418 Method to treat melanoma in BRAF inhibitor-resistant subjects
•••
Patent Inventor Names
Gordon Bray
Iris Chan
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11783366
Patent Primary Examiner
‌
Raymond J. Henley, III
CPC Code
‌
A61P 17/00
‌
A61P 35/00
‌
A61P 35/04
‌
A61K 31/375
‌
A61K 31/397

Find more entities like US Patent 11783366 Combination therapies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo